Related Experiment Videos
Cytokines in tumor therapy. Interleukin-3
R Kurzrock1, Z Estrov, M Talpaz
1Department of Clinical Immunology and Biological Therapy, University of Texas M.D. Anderson Cancer Center, Houston 77030.
American Journal of Clinical Oncology
|January 1, 1991
Summary
Interleukin-3 (IL-3) shows promise in treating pancytopenia by expanding blood cell precursors. Combining IL-3 with other growth factors may enhance blood cell maturation and function in clinical settings.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Interleukin-3 (IL-3) is a cytokine derived from T-cells.
- It stimulates multipotential progenitor cells, showing clinical potential for pancytopenia therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of IL-3 in human subjects.
- To explore the potential of IL-3 in combination with other growth factors for blood cell development.
Main Methods:
- Early phase I clinical trials in human subjects.
- In vitro colony/culture assays and in vivo patient studies.
Main Results:
- IL-3 is well-tolerated with no observed progression to acute leukemia in preleukemic states.
- Increased neutrophil, eosinophil, platelet, and reticulocyte counts were observed, though responses varied.
- In vitro findings partially predicted in vivo changes in granulocyte and monocyte counts.
Conclusions:
- IL-3 has a short half-life, necessitating routes for prolonged serum levels.
- Future trials should investigate IL-3 alone and in combination with other growth factors like GM-CSF, G-CSF, and erythropoietin.